GSK will use the Breath Biopsy to assess whether the right treatment for the right patient can be identified, and to evaluate its drug candidate for COPD.
The partners plan to validate blood-based microRNAs as biomarkers for the early detection of pulmonary and neurodegenerative diseases.
The firm also has Periplex tests in development for sepsis, urinary tract infections, and chronic obstructive pulmonary disease.
